"Critics have complained that a drug industry got a sweetheart deal when it struck a bargain with the White House and Senate Finance Committee over health care reform.
There's new reason to think those critics were right. It comes from an October forecast by IMS Health, a respected global research and consulting firm." -- Jonathan Cohn, TNR. |